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In the past decades, the field of prostate cancer (PCa) biology has developed exponentially and paralleled with that
has been the growing interest in translation of laboratory findings into clinical practice. Based on overwhelming
evidence of high impact research findings which support the underlying cause of insufficient drug efficacy in
patients progressing on standard androgen deprivation therapy (ADT) is due to persistent activation of the
androgen receptor (AR) signaling axis. Therefore, newer agents must be discovered especially because newer ADT
such as abiraterone and enzalutamide are becoming ineffective due to rapid development of resistance to these
agents. High-throughput technologies are generating massive and highly dimensional genetic variation data that
has helped in developing a better understanding of the dynamic repertoire of AR and AR variants. Full length AR
protein and its variants modulate a sophisticated regulatory system to orchestrate cellular responses. We partition
this multicomponent review into subsections addressing the underlying mechanisms of resistance to recent
therapeutics, positive and negative regulators of AR signaling cascade, and how SUMOylation modulates AR
induced transcriptional activity. Experimentally verified findings obtained from cell culture and preclinical studies
focusing on the potential of natural agents in inhibiting mRNA/protein levels of AR, nuclear accumulation and
enhanced nuclear export of AR are also discussed. We also provide spotlight on molecular basis of enzalutamide
resistance with an overview of the strategies opted to overcome such resistance. AR variants are comprehensively
described and different mechanisms that regulate AR variant expression are also discussed. Reconceptualization
of phenotype- and genotype-driven studies have convincingly revealed that drug induced resistance is a major
stumbling block in standardization of therapy. Therefore, we summarize succinctly the knowledge of drug resistance
especially to ADT and potential avenues to overcome such resistance for improving the treatment outcome of
PCa patients.
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Androgen receptor (AR) blockers have been incorpo-
rated in the backbone of PCa therapeutics. Mutation
and amplification of AR gene, growth factor mediated
signaling induced activation of AR, overexpression of
nuclear receptor co-activators, alternative splicing vari-
ants and steroid metabolism enzymes are widely studied
biological mechanisms that underpin castration resistant
prostate cancer (CRPC) phenotype. Substantial fraction
of information has been added into the existing pool of
knowledge, and dysregulation of intracellular signaling* Correspondence: ammadahmad638@yahoo.com
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unless otherwise stated.networks in PCa lends credence to the mantra that in-
creasing molecular understanding is catalyzing the gen-
eration of AR antagonists. Mounting evidence has
provided a platform to investigate systematically not
only the molecular complexity of CRPC, leading to the
identification of disease pathways and modules, but also
changes in the recruitment and regulatory effect of AR
on transcription as PCa progresses.
First generation AR antagonists such as bicalutamide
and nilutamide gained appreciation but agonistic proper-
ties were noted in AR over-expressing PCa cells, which
raised some concerns for the use of these agents in human
PCa patients. Whereas, enzalutamide was reported to be
effective against AR over-expressing PCa cells and proved
to be a valuable addition in the arsenal of molecularentral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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FDA. VCaP prostate cancer cells have endogenously amp-
lified AR gene and enzalutamide exerted inhibitory effects
on proliferation of VCaP cells. Moreover, the activity of
mutation bearing AR (W741C) was also notably reduced
upon treatment with enzalutamide. Bicalutamide induced
AR conformational change facilitated its interaction with
FxxLF or LxxLL motif-containing co-activators. On the
contrary, enzalutamide did not promote AR interaction
with co-activators. We will now address some specific ex-
ample of AR activation in the context of CRPC and subse-
quent metastasis (mCRPC) of PCa.
Current treatment options for PCa patients
Lupron and other LHRH agonists are worthwhile op-
tions as part of ADT for PCa patients. Using multi-
pronged approach, by combining antagonists such as
bicalutamide with Lupron can prevent its harmful side
effects [1]. There are now more treatment modalities as
summarized below such as ARN-509, enzalutamide and
abiraterone and their pros and cons are being discussed.
Lower treatment dose of ARN-509 and absence of any
risk of seizures in patients as compared to enzalutamide
treatment makes it a potent anti-androgen than enzalu-
tamide. However, F876L mutant AR carrying cancer cell
lines did not show any response to ARN-509. Moreover,
F876L mutant AR was identified in plasma DNA from
ARN-509-treated patients with progressive CRPC [2].
CYP17 is also chemically inhibited by Orteronel, also
known as TAK-700. Considerably higher specificity for
17,20-lyase than for 17α-hydroxylase by Orteronel is a
hallmark feature that differentiates it from abiraterone.
More importantly, Orteronel associated manageable tox-
icities and its chronic administration without steroids
makes it a drug of choice. Orteronel induced durable de-
clines in PSA in mCRPC patients [3].
Although there are encouraging advancements in our
understanding related to the intricacies that mediate an-
drogen metabolism and thereby regulate AR activation
[4], we still need in-depth analysis and identification of
agents perhaps natural agents (no known toxicity in hu-
man) that can overcome resistance against current and
next-generation AR targeting agents.
Positive and negative regulators of AR and AR
induced signaling
Substantial information has been added into the landscape
of co-activator/co-repressor complexes associated with
AR (Figure 1), and it is now known that AR interacted
with phosphorylated heterogeneous nuclear ribonucleo-
protein K (hnRNP K) in nuclear matrix region in PCa
cells. However, astonishingly, bicalutamide treatment
reduced phosphorylated hnRNP K levels and induced
its dissociation from AR [5]. Nuclear accumulation of ARis notably reduced by HepaCAM in PCa cells [6]. SPOP
E3 ubiquitin ligase has been shown to degrade full-length
AR by recognizing a Ser/Thr-rich degron in its hinge
domain [7].
MID1 is a microtubule-associated ubiquitin E3 ligase
frequently overexpressed in PCa cells. MID1 bound
purine-rich repeats regions in AR mRNA have been
identified experimentally. Targeted inhibition of MID1
in AR overexpressing DuCaP cells notably reduced de-
creased protein levels of AR [8]. Skp2 (S-phase kinase-
associated protein 2) is an E3 ubiquitin ligase reported
to enhance AR degradation via ubiquitination. K847R
mutant AR did not show Skp2 mediated ubiquitination
at the mutant residue [9,10]. SET8 is a methyltransferase
reported to methylate Histone H4 Lys 20 of the pro-
moter of AR target gene PSA. Androgen stimulation
promoted enrichment of SET8 at promoter region of AR
target gene where it co-existed with AR [11] (Figure 1).
Jumonji domain-containing demethylase, KDM4C is a
well known protein reported to enhance AR mediated
transcriptional activity by modulating H3K9 demethyla-
tion. Interfering with KDM4C in LNCaP cells dramatic-
ally impaired AR induced transcriptional up-regulation
of TMPRSS2, KLK3 and KLK2. SD70 contains an 8-
hydroxyquinoline moiety that is an Fe(II) chelator with
considerable activity against KDM4. SD70 treated PCa
cells and displayed a marked decrease in AR target gene
expression [12,13].
AR induced signaling as targets for PCa therapy
Small Ubiquitin-Related Modifier (SUMO) mediated
control of AR and associated protein network as target
for therapy
This section reviews mounting research work summariz-
ing information on alteration in transcriptional network
of sumoylated AR, various ways in which AR and its as-
sociated proteins are SUMOylated and how SENP-1
deconjugates SUMO from AR to enhance AR induced
expression of target genes. Targeting of SENP-1 using
chemical and synthetic agents is also discussed.
It has previously been convincingly revealed that N-
terminal transactivation domain of AR undergoes covalent
modification by SUMOs at two conserved lysine that may
influence AR efficiency in stimulating expression of target
genes. Increasingly it is being realized that SUMOylated
AR shows a lower transcriptional activity (Figure 2). It is
noteworthy that PC-3 cells stably expressing doubly
SUMOylation site-mutated AR displayed a higher apop-
totic rate [14,15]. 15-deoxy-Δ(12,14)-prostaglandin J(2) is
also reported to trigger SUMOylation of AR [16]. In ac-
cordance with significant roleplay of SUMOylation, it has
also been reported that mutation of the FOXA1 SUMOy-
lation sites considerably reduced AR nuclear mobility.
Forkhead box (FOX) protein A1 is involved in chromatin
Figure 1 Showing inactive and active states. a) Co-repressors and HDAC are recruited in the absence of AR. b) AR induced positioning of
co-activators, Histone Acetyltransferases. c) SET8 a histone Methytransferase co-exists with AR.
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[14,15]. Gly residue is present at 524th position down-
stream to the core of the second synergy control motif
in AR. AR bearing the G524D substitution displayed
a higher transcriptional activity than wild type AR.Figure 2 Natural and synthetic agents mediated targeting of AR. a) SU
SENP-1 is a target of AR that deconjugated SUMO from AR thus enhancing
have shown potent inhibitory effects on SENP-1. e) AZD3514 inhibited nuc
AR. g) Urolithins and Curcumin have shown to reduce AR induced transcrip
levels of AR.Moreover, SUMOylation-deficient AR mutant (K386R/
K520R), also induced significant target gene expression
[17]. Heat stress resulted in generation of prominent
intranuclear granules that contained SUMO-2/3 and
AR. Stress induced SUMOylated AR transportationMOylated AR mediated transcriptional activity activity is reduced. b-c)
AR mediated transcriptional activity. d) Natural and synthetic agents
lear accumulation of AR. f) Mahanine promoted nuclear export of
tional activity. h) Natural agents also decrease mRNA and protein
Table 1 List of natural agents with notable activity









Curcumin AR inhibition Zhou et al. [25]
Imidazopyridine PI3K/Akt ↓ Muniyan et al. [26]
AR induced signaling ↓
Atraric acid Inhibition of intramolecular
amino/carboxy (N/C)-terminal






Yang et al. [28]
AZD3514 AR ↓ Loddick et al. [31]
Rosmarinus
officinalis extract
AR ↓ Petiwala et al. [29]
Betulinic acid AR ↓ Reiner et al. [30]
Isochaihulactone AR mRNA ↓ Liu et al. [33,34]
Shikonin AR protein ↓ Jang et al. [32]
Arrow indicates inhibition and/or downregulation of target proteins.
Farooqi and Sarkar Cancer Cell International  (2015) 15:7 Page 4 of 9towards nuclear matrix. Quantitative chromatin immu-
noprecipitation (qChIP) assay has provided clear evi-
dence of detachment of androgen-loaded AR from
regulatory regions of these genes in Heat stressed pros-
tate cancer cells. Using anti-SUMO-2/3 antibody, it was
shown that heat stressed prostate cancer cells showed
accumulation of SUMO-2/3 in the AR-binding regions
of the target genes [18]. Rapidly emerging experimental
findings are also providing new information regarding
positive regulators of AR induced signaling. SUMO-
specific protease 1 (SENP1) has previously been identi-
fied as an AR regulated gene and reportedly decreased
SUMOylation of AR via deconjugation of AR-SUMO
covalent bond [19] (Figure 2). Triptolide, isolated from
Tripterygium wilfordii Hook notably inhibited SENP1
that consequently resulted in a markedly reduced
SUMOylated AR induced transcriptional activity [20].
Benzodiazepine-based inhibitors and 2-(4-Chlorophe-
nyl)-2-oxoethyl 4-benzamidobenzoate derivatives have
shown potential in targeting of SENP1 [21,22] (Figure 2).
These recent reports suggest that newer arsenals are be-
ginning to emerge for AR-targeted therapeutics which
could be useful in improving the therapeutic outcome
of PCa patients especially for patients with CRPC and/
or mCRPC.
Natural and Synthetic agents mediated targeting
of AR for PCa therapy
Here we will provide some examples of a number of
natural agents or their synthetic analog as AR-targeted
therapeutics. Epibrassinolide (EBR) is a member of the
brassinosteroids (BR) with notable activity against LNCaP
prostate cancer cells expressing functional AR. EBR
exerted its biological effects via activation of polyamine
catabolic machinery in prostate cancer cells. Interfering
with spermidine-spermineacetyltransferase (SSAT), an es-
sential enzyme in polyamine catabolic machinery, dramat-
ically impaired EBR induced apoptosis [23].
Urolithins, Walnut polyphenol metabolites have been
shown to inhibit AR mediated upregulation of PSA in
LNCaP cells (Figure 2). Data obtained from EMSA re-
vealed that AR did not bind to response elements of
PSA after treatment with Urolithins. Moreover, levels of
Bcl-2, an anti-apoptotic protein were reduced signifi-
cantly [24]. Shown in Table 1.
Curcumin analogues efficiently inhibited AR activity in
prostate cancer cells [25].
Imidazopyridine derivatives have been shown to in-
hibit both PI3K/Akt and AR induced signaling in LNCaP
cells [26]. Atraric acid (AA) isolated from bark of
Pygeum africanum considerably blocked intramolecular
amino/carboxy (N/C)-terminal interaction of the AR
[27]. Furanoditerpenoid spongia-13(16),-14-dien-19- oic
acid has been shown to block essential N/C interactionsrequired for AR transcriptional activity. It was also noted
to effectively bind ligand binding domain of AR [28].
Shown in Table 1.
C/EBP homologous protein was noted to be an essen-
tial regulator of AR degradation in Rosmarinus officinalis
extract-treated 22Rv1 and LNCaP cells [29]. Levels of
AR were reduced in LNCaP and in AR transfected PC3/
DU145 cells upon treatment with plant-derived small
molecule Betulinic acid (BA) [30]. Shown in Table 1.
AZD3514, an orally bioavailable drug has potent activ-
ity against AR induced signaling. AZD3514 exerted in-
hibitory effects on AR expression and ligand-driven
nuclear accumulation of AR [31]. Shown in Table 1. Shi-
konin, a natural naphthoquinone isolated from Zi Cao
(gromwell) repressed mRNA and protein expression of
AR [32] (Figure 2). Shown in Table 1. Racemic forms of
natural compound isochaihulactone also inhibited AR
mRNA and protein expression [33,34] (Figure 2). It has
recently been persuasively revealed that genistein, a soy
phytoestrogen induced apoptosis in T877A mutant AR
expressing LNCaP cells at higher doses. Moreover
T877A, W741C and H874Y expressing PC-3 cells also
displayed similar responses upon treatment with higher
doses of genistein [35]. More importantly, it is note-
worthy that a natural agent isolated from leaves of
Murraya koenigii promoted shuttling of AR from nu-
cleus to cytoplasm. Ligand-induced AR phosphorylation
at Ser-81 was also notably repressed in Mahanine treated
prostate cancer cells [36]. Novel Nor-Homo- and Spiro-
Oxetan- Steroids have considerable activity against full
length and T877A mutation carrying AR [37].
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surfaced exposed pocket on DNA binding domain of AR
and targeting of this site considerably inhibited tran-
scriptional activity of full-length AR and its splice vari-
ants [38]. Methylselenol and MDV3100 synergistically
inhibited full length AR and AR-V7 in prostate cancer
cells [39]. We will further discuss the role of enzaluta-
mide and how one could potentially device strategies for
overcoming enzalutamide resistance.
Enzalutamide as an important AR-targeting agent
There are some exciting pieces of evidences obtained from
in-vitro studies that have started to shed light on the
underlying mechanisms of enzalutamide resistance. Signifi-
cant inhibition of AR nuclear accumulation by enzaluta-
mide was documented in a wide ranging cell culture and
pre-clinical studies. However, in a recent study nuclear ac-
cumulation of full length AR was noted in androgen de-
pleted PCa cells expressing either AR-V7 or ARv567es.
Mice inoculated with AR-V7-knockdown cells were sensi-
tive to enzalutamide induced tumor growth inhibition. Ser-
ial passage of the relapsed tumors in enzalutamide treated
castrated mice gave rise to the tumors that were enzaluta-
mide resistant. RNA-seq analysis revealed upregulated ex-
pression of ARv567es and AR-V7 in resistant tumors [40].
There is recent evidence suggesting that enzalutamide
exposure induced glucocorticoid receptor (GR) expression
in prostate cancer cells. Mechanistically it was shown that
enzalutamide exerted growth inhibitory effects but co-
treatment with Dexamethasone (Dex) reversed this growth
inhibition. More importantly gene silencing of GR re-
stored sensitivity of cancer cells to enzalutamide. Data ob-
tained from ChIP-seq experiments indicated that AR
bound DNA binding sites identified after DHT treatment
were bound by GR after Dex treatment [41].
AZD5363 and enzalutamide have been shown to delay de-
velopment of resistance against enzalutamide in preclinical
models. Combinatorial approach effectively induced regres-
sion of tumor in xenografted mice at time of castration [42].
Enzalutamide exposure induced autophagic response
in prostate cancer cells that operated through activation
of AMP-dependent protein kinase (AMPK) and the sup-
pression of mammalian target of rapamycin (mTOR).
Gene silencing of AMPK inhibited autophagic response
and induced apoptosis. Combinatorial approach consist-
ing of enzalutamide and autophagy inhibitors notably
inhibited tumor growth in mice orthotopically implanted
with ENZA-resistant cells [43]. However, it has also been
shown that enzalutamide was not effective in patients
previously treated with docetaxel [44].
Enzalutamide induced infiltration and metastasis
There is a direct piece of evidence emphasizing on the fact
that Enzalutamide or bicalutamide increased macrophageinfiltration in prostate cancer cells that resulted in an
enhanced prostate cancer cell invasion. Mechanistically
it was shown that Enzalutamide or bicalutamide downreg-
ulated AR-induced PIAS3 expression and enhanced
pSTAT3-CCL2 signaling cascade. ASC-J9, an AR degrad-
ation enhancer exerted inhibitory effects on STAT3 phos-
phorylation/activation. CCR2 antagonist treatment also
impaired Enzalutamide or bicalutamide mediated increase
in cell invasion [45]. It has been experimentally verified
that prostate cancer cells enhanced chemokine-CXCL9 in-
duced recruitment of CD4(+) T cells than the surrounding
normal prostate cells. Suppression of AR signals either
through gene silencing or enzalutamide enhanced the re-
cruitment of T cells [46].
Improving the Efficacy of Enzalutamide by targeting of
Twist and SRD5A
Twist is involved in epithelial-to-mesenchymal transition
and metastasis and a therapeutic target. Co-treatment
with Enzalutamide and vaccine directed against Twist
resulted in considerably enhanced overall survival of
TRAMP mice [47]. Steroid 5-alpha-reductases (SRD5A1
and SRD5A3) are overexpressed in different prostate can-
cer cell lines. Proliferation potential of SRD5A1 and
SRD5A3 overexpressing cancer cells was notably reduced
upon treatment with Dutasteride and Enzalutamide [48].
C2-substitution with benzyl and phenyl moieties is a re-
markable advancement in improving efficacy of androgen
receptor Pan-antagonists as evidenced by efficient tumor
growth inhibition in xenografted mice [49].
Niclosamide, an FDA-approved antihelminthic drug effi-
ciently induced AR-V7 protein degradation and AR-V7
mediated transcriptional activity [50,51]. Inhibition of
allosteric site of the AR binding function 3 (BF3) using
1H-indole-2-carboxamides also exerted inhibitory effects
on proliferation potential of enzalutamide-resistant pros-
tate cancer cell lines [52]. In the following section, we will
discuss further on the potential role of AR splice variants
and therapeutic resistance.
Androgen receptor variants in defining the
complexity of PCa
It is becoming progressively more understandable that
AR gene rearrangements stimulated expression of trun-
cated AR variant proteins lacking the AR ligand-binding
domain and synthesis of full-length AR was repressed.
AR variant proteins tactfully induced AR transcriptional
network in the absence of full-length AR or androgens
[53]. It has been verified that castration induced marked
increase in intratumoral androgen biosynthesis. More-
over, full-length AR and AR splice variants were also
upregulated [54]. There is rapidly increasing scientific
evidence emphasizing on the fact that androgen depletion
induced AR splice variants (ARVs) in prostate cancer cells
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bound AR exerted inhibitory effects on Androgen Receptor
Variant-7 (AR-V7) expression by stimulating expression of
proteins that suppressed AR-V7 expression. AR-V7 protein
expression was low relative to AR-FL in androgen-deprived
VCaP cells and mice xenografted with castration-resistant
VCaP cancer cells [55]. However, previous intriguing piece
of evidence emphasized on the fact that that some ARVs
are functionally active independently in the absence of
AR-FL to activate AR reporter constructs. Transfecting
AR-negative DU145 cells independently with three ARVs
truncated after exon 3 (AR-V1, mAR-V2 and AR-V7) re-
vealed that AR-V7 and mAR-V4 (truncated after exon 4)
indicated notable activity. Another important finding of the
study was that gain of function of ARV7 was impaired in
presence of dominant negative AR-V1 in PCa cells [56].
It has also been highlighted in a recent report that an-
drogen depletion considerably enhanced interactions be-
tween splicing factors and AR pre-mRNA as evidenced
by identification of two RNA splicing enhancers and
their binding proteins ASF/SF2 and U2AF65 ([50,51].
AR8 lacks a DNA binding domain and is structurally dif-
ferent from other known AR splice variants. Surpris-
ingly, AR8 localized primarily on the plasma membrane,
probably through palmitoylated cysteine residues present
within its C-terminal region. However, mutation of resi-
dues resulted in abrogation of post-translational modifi-
cation and consequently loss of AR8 from plasma
membrane. Considerably enhanced tyrosine phosphoryl-
ation of AR was noted in AR8 overexpressing prostate
cancer cells upon treatment with EGF. Structurally, AR
was noted to co-exist with EGFR and Src in EGF treated
AR8 overexpressing prostate cancer cells [57].
Previously, it has been shown that microtubule-associated
motor protein, dynein triggered nuclear import of AR.
Moreover, overexpressing dynactin associated protein
dynamitin in cancer cells considerably reduced dynein-
cargo interaction and nuclear accumulation. Microtubule-
interacting ARv567 was sensitive to taxane and docetaxel
treatment was significantly effective in ARv567-expressing
LuCap86.2 tumor xenografts [58]. AR and AR-V7 differ-
entially activated target genes in co-operation with FOXA1
[59]. Circumstantial evidence also indicated that AR-Vs
interacted with DNA independently of full-length AR in
the absence of androgen to mediate a unique gene network
[60]. Prostate cancer cells expressing constitutively ac-
tive, C-terminally truncated low molecular weight AR-
species lacking the AR-ligand binding domain (LBD)
has added another layer of complexity in the targeting.
Detailed mechanistic insights indicated that full length
AR undergo heterodimerization with an ARΔLBD in an-
drogen depleted prostate cancer cells. Stilbene and fluori-
nated dialkylaminostilbene (FIDAS) considerably inhibited
AR activity in prostate cancer cells co-transfected withconstitutively active ARΔLBD-variant Q640X and an AR-
dependent reporter gene [61].
ARv567es, in which exons 5, 6, and 7 are deleted, is an AR
variant notably involved in cancer progression. For a better
understanding of the ARv567es mediated prostate cancer
progression, probasin (Pb) promoter-driven ARv567es trans-
genic mouse was developed. Detailed analysis revealed that
ARv567es induced epithelial hyperplasia after 16 weeks and
invasive adenocarcinoma was noted after 1 year in mice
[33,34]. AR-V7 mediated cancer progression has recently
been studied in transgenic mouse model (AR3Tg) and re-
sults revealed that AR-V7 induced an expansion of prostatic
progenitor cell population that consequently resulted in de-
velopment of prostatic intraepithelial neoplasia. Additionally
gene network associated with Epithelial to Mesenchymal
transition was also noted to be activated [62].
It is also interesting to note that although gene net-
work reported to be regulated by full length AR and
C-terminally truncated variant of AR is overlapping,
there are some genes which are exclusively triggered by
AR variant, specifically, RHOB which is shown to be in-
volved in the increased migration [63], and thus target-
ing RHOB could become a novel therapeutic strategy for
PCa patients.
The broader role of NF-κB signaling in PCa
relevant to AR signaling
Classical NF-κB intracellular signaling operating through
p65/p50 heterodimer is constitutively activate in prostate
cancer cells. Noncanonical NF-κB pathway involves the
processing of p100 to NF-κB2/p52 and prostate cancer
cells chronically treated with Enzalutamide have been
shown to display higher levels of NF-κB2/p52. NF-κB2
expressing LNCaP and C4-2B cells had a higher expres-
sion of AR-V7 splice variant. NF-κB2 silencing in VCaP
and CWR22Rv1 cells significantly reduced AR-V7 splice
variant expression [64]. It is interesting to note that
nuclear factor-kappa B (NF-κB) signaling triggered expres-
sion of androgen receptor variants. Using a combinatorial
anti-androgen and NF-κB-targeted therapy efficiently re-
duced tumor growth in xenografted mice [12,13].
Activators and inhibitors of AR variants
Vav3, a Rho GTPase guanine nucleotide exchange factor
is involved in enhancing transcriptional activity of AR3
and ARv567es. Interfering with Vav3 resulted in signifi-
cantly reduced nuclear accumulation of AR3 and data
obtained from co-immunoprecipitation assay revealed
that Vav3 interacted with AR3 [65]. In accordance with
this concept, another protein reported to inhibit activity
of AR variant is FOXO1. In-depth analysis indicated
that AKT mediated phosphorylation of FOXO1 exported
it from nucleus thus allowing AR-V7 to transcriptionally
upregulate expression of target genes. However, chemical
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of FOXO1 that consequently inhibited AR-V7 activity [66].
Recently it has been reported that N-terminal tau5/AF5 do-
main (aa392-558) of AR is required for binding to Gli2, a
transcription factor in the Hedgehog pathway. Confluence
of information suggested that Gli2 C-Terminal Domain
and Full Length Gli2 remarkably enhanced AR-V7 and
AR567es transcriptional activity. Gli2 bound AR was noted
at chromatin sites near to androgen responsive genes in
Gli2 overexpressing LNCaP cells [9,10].
Conclusion and perspectives
Emerging evidence as presented in this short review art-
icle clearly suggesting that the development of novel
AR-targeting agents is not a distant possibility any more,
and such developments are welcome news for PCa pa-
tients especially for those who develop CRPC and subse-
quent mCRPC after ADT. In the context of ADT
especially the introduction of novel ADTs such as enza-
lutamide and abiraterone is a significant therapeutic ad-
vancement for the treatment of PCa; however, these
agents are rapidly developing resistance largely contrib-
uted by the expression of AR variants and other resist-
ance pathways. Therefore any developments of novel
strategies for overcoming resistance to ADT or delaying
and/or preventing the development of resistance would
revolutionize in the better treatment of PCa patients
after the surgical management.
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